In previous work, we synthesized cholesteronitrone ChN2 [42,43], derived from the structure of olesoxime (cholest-4-en-3-one), a cholesterol-based molecule initially developed in 2007 as a therapeutic candidate for amyotrophic lateral sclerosis (ALS) and shown to possess neuroprotective properties in preclinical models of various neurodegenerative diseases [45,46]. This evidence concerns the gene CHN2 and amyotrophic lateral sclerosis.